Structure-based antigen design: a strategy for next generation vaccines.
Vaccine design is progressing from empiricism towards the increasingly rational presentation of the targets of protective immunity. Nevertheless, most current vaccine antigens are essentially the native macromolecules of pathogens. These molecules are adapted to evade, not induce, immunity. High resolution structures reveal the electrostatic surfaces recognized by neutralizing antibodies and the architectures underlying these surfaces, thereby identifying which substructures must be left intact and which can be changed to optimize biochemical and immunologic performance. Armed with detailed structural information, we can engineer optimized antigens that are more stable, homogeneous, and efficiently produced, making immunization more practical and affordable. Understanding the structural basis for immunogenicity and immunodominance will allow us to improve vaccine efficacy and broaden the range of vaccine-preventable diseases.
Dormitzer
Philip R
PR
Novartis Vaccines and Diagnostics, Inc., 350 Massachusetts Ave., Cambridge, MA 02139, USA. philip.dormitzer@novartis.com
Ulmer
Jeffrey B
JB
Rappuoli
Rino
R
D000941:Antigens / Q000737:chemistry / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use*; D018604:Epitope Mapping / Q000639:trends*; D005544:Forecasting; D007114:Immunization / Q000639:trends*; D015202:Protein Engineering / Q000639:trends*; D014612:Vaccines / Q000627:therapeutic use*
D000941:Antigens; D014612:Vaccines